Dendritic nanocarrier

A. Garcia-Bernabe, M. Kramer, B. Olah, R. Haag, Syntheses and phase-transfer properties of dendritic nanocarriers that contain perfluorinated shell structures, Chem. Eur. J. 10 (2004) 2822-2830. 

Due to their amphiphilic nature, dendritic nanocarriers can transport various dmg and dye molecules very efficiently and form defined aggregates, which have been revealed by DLS as well as cryo-TEM measurements (cf. Eig. 1.2). These nanocarrier aggregates can disassemble upon dilution into individual CMS particles, thereby releasing the active agent. Finally, they are excreted through the kidneys, thus avoiding long-term toxicity due to accumulation in vivo. 

In order to overcome the limitations associated with siRNA delivery in vivo, a group of dendritic nanocarriers derived either fromPG or PEI were synthesized and their silencing efficiency was evaluated. Among the nanocarriers evaluated in this study, the best siRNA transfection efficiency with regard to toxicity was observed for PG amine. In general, successful systemic delivery... 

Ofek P, Fischer W, Calderon M et al (2010) In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J 24 3122-3134... 

Minko and co-workers linked paclitaxel via succinate linker to PAMAM G4 dendrimers and could show that the drug could be released when the ester bonds were hydrolyzed by esterases. The dendritic carrier was more efficient in cell internalization and showed better cytotoxicity than the free drug and a linear PEG-drug conjugate which proves that dendritic nanocarriers are a highly potent drug delivery platform [82]. 

Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumour cells, as well as tumour neovasculature) are key targets [280]. 

Clearly, dendritic polymers may be ntilized as nanocarriers for the improved delivery of antitnmor agents. They offer several advantages over conventional polymers. 

In this chapter, the design of stmcturally defined dendritic and protein-based polyelectrolyte nanocarriers is presented and the impact of their macromolecular architectures and the presence of multiple charges and charge densities on cellular uptake, trafficking, and cell toxicity is discussed. 

Calderdn, M., Quadir, M. A., Strumia, M. and Haag, R. (2010). Functional dendritic polymer architectures as stimuli-responsive nanocarriers. Biochimie, 92, 1242-1251. 

The problems of bio-functional polymers were diseussed on the 4 session. This session included 6 lectures. The speakers gave information about biofunctional dendritic architectures, biocompatible and bioactive polymers containing saccharide fimctionality, design and mechanisms of antimicrobial polymers, control of protein adsorption on functionalized electrospun fibers, microcapsules and nanoparticles for controlled delivery and repair, smart nanocarriers for bioseparation and responsive drug delivery systems. 

Radowski, M.R. cr al. (2007) Supramolecular aggregates of dendritic multishell architectures as universal nanocarriers. Angewandte Chemie-Intemational Edition, 46,1265-1269. 

Ideta, R., Tasaka, R, Jang, W. D., Nishiyama, N., Zhang, G. D., Harada, A., Yanagi, Y, Tamaki, Y., Aida, T., and Kataoka, K. 2005. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer. Nano Lett 5(12), 2426-2431. 

---